JP2024150751A5 - - Google Patents

Download PDF

Info

Publication number
JP2024150751A5
JP2024150751A5 JP2024127900A JP2024127900A JP2024150751A5 JP 2024150751 A5 JP2024150751 A5 JP 2024150751A5 JP 2024127900 A JP2024127900 A JP 2024127900A JP 2024127900 A JP2024127900 A JP 2024127900A JP 2024150751 A5 JP2024150751 A5 JP 2024150751A5
Authority
JP
Japan
Prior art keywords
antibody
seq
sequence
tslp
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024127900A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024150751A (ja
Filing date
Publication date
Priority claimed from JP2019555854A external-priority patent/JP7330896B2/ja
Application filed filed Critical
Publication of JP2024150751A publication Critical patent/JP2024150751A/ja
Publication of JP2024150751A5 publication Critical patent/JP2024150751A5/ja
Priority to JP2025147176A priority Critical patent/JP2025170430A/ja
Pending legal-status Critical Current

Links

JP2024127900A 2017-04-12 2024-08-02 抗tslp抗体による喘息治療 Pending JP2024150751A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025147176A JP2025170430A (ja) 2017-04-12 2025-09-04 抗tslp抗体による喘息治療

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201762484864P 2017-04-12 2017-04-12
US62/484,864 2017-04-12
US201762553575P 2017-09-01 2017-09-01
US201762553477P 2017-09-01 2017-09-01
US62/553,477 2017-09-01
US62/553,575 2017-09-01
JP2019555854A JP7330896B2 (ja) 2017-04-12 2018-04-12 抗tslp抗体による喘息治療
JP2023080295A JP2023099233A (ja) 2017-04-12 2023-05-15 抗tslp抗体による喘息治療

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023080295A Division JP2023099233A (ja) 2017-04-12 2023-05-15 抗tslp抗体による喘息治療

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025147176A Division JP2025170430A (ja) 2017-04-12 2025-09-04 抗tslp抗体による喘息治療

Publications (2)

Publication Number Publication Date
JP2024150751A JP2024150751A (ja) 2024-10-23
JP2024150751A5 true JP2024150751A5 (enExample) 2025-04-28

Family

ID=62092313

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019555854A Active JP7330896B2 (ja) 2017-04-12 2018-04-12 抗tslp抗体による喘息治療
JP2023080295A Withdrawn JP2023099233A (ja) 2017-04-12 2023-05-15 抗tslp抗体による喘息治療
JP2024127900A Pending JP2024150751A (ja) 2017-04-12 2024-08-02 抗tslp抗体による喘息治療
JP2025147176A Pending JP2025170430A (ja) 2017-04-12 2025-09-04 抗tslp抗体による喘息治療

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2019555854A Active JP7330896B2 (ja) 2017-04-12 2018-04-12 抗tslp抗体による喘息治療
JP2023080295A Withdrawn JP2023099233A (ja) 2017-04-12 2023-05-15 抗tslp抗体による喘息治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025147176A Pending JP2025170430A (ja) 2017-04-12 2025-09-04 抗tslp抗体による喘息治療

Country Status (21)

Country Link
US (3) US10828365B2 (enExample)
EP (1) EP3609917A1 (enExample)
JP (4) JP7330896B2 (enExample)
KR (2) KR102666879B1 (enExample)
CN (1) CN110573525A (enExample)
AU (2) AU2018253118B2 (enExample)
BR (1) BR112019021482A2 (enExample)
CA (1) CA3059364A1 (enExample)
CL (1) CL2019002897A1 (enExample)
CO (1) CO2019011462A2 (enExample)
IL (1) IL269791B (enExample)
JO (1) JOP20190243A1 (enExample)
MX (1) MX2019012158A (enExample)
MY (1) MY207509A (enExample)
PE (1) PE20200484A1 (enExample)
PH (1) PH12019502331A1 (enExample)
SG (1) SG11201909322VA (enExample)
TN (1) TN2019000289A1 (enExample)
TW (2) TWI856945B (enExample)
UY (1) UY37676A (enExample)
WO (1) WO2018191479A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3347377T (pt) * 2015-09-09 2021-04-30 Novartis Ag Anticorpos que se ligam à linfopoietina do estroma tímico (tslp) e métodos de utilização dos anticorpos
JOP20190243A1 (ar) * 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp
CN116751295A (zh) 2019-06-04 2023-09-15 江苏恒瑞医药股份有限公司 能结合胸腺基质淋巴细胞生成素的抗体及其应用
EP3996747A4 (en) * 2019-07-11 2023-08-16 Tavotek Biotherapeutics (Hong Kong) Limited AGENTS THAT INTERFERE WITH THYMIC STROMAL LYMPHOPOIETIN RECEPTOR (TSLP) SIGNALING
JP7331298B2 (ja) * 2019-09-04 2023-08-23 ビオシオン インコーポレイテッド 抗体結合tslp及びその使用
MX2022005083A (es) * 2019-10-28 2022-07-19 Medimmune Ltd Formulaciones en polvo seco de anticuerpos de unión a linfopoyetina estromal tímica (tslp) y métodos para usarlos.
CN114887053A (zh) * 2019-11-29 2022-08-12 康诺亚生物医药科技(成都)有限公司 一种tslp相关病症治疗剂的开发和应用
CA3155759A1 (en) * 2019-12-13 2021-06-17 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anti-tslp antibody and uses thereof
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法
WO2021163588A1 (en) * 2020-02-13 2021-08-19 Amgen Inc. Treatment of atopic dermatitis with anti-tslp antibody
BR112022016010A2 (pt) * 2020-02-13 2022-12-20 Amgen Inc Formulações de anticorpos anti-tslp humanos e métodos de tratamento de doenças inflamatórias
CA3167975A1 (en) * 2020-02-18 2021-08-26 Amgen, Inc. Formulations of human anti-tslp antibodies and methods of using the same
CN113388035A (zh) * 2020-03-13 2021-09-14 迈威(上海)生物科技股份有限公司 特异性针对人tslp的抗体及其应用
WO2022117079A1 (zh) * 2020-12-03 2022-06-09 江苏恒瑞医药股份有限公司 结合胸腺基质淋巴细胞生成素的抗体及其应用
CN113501878B (zh) * 2021-02-03 2022-12-02 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
CN114853888B (zh) * 2021-02-05 2023-11-03 上海洛启生物医药技术有限公司 抗tslp纳米抗体及其应用
CN116897053B (zh) * 2021-03-03 2025-01-07 正大天晴药业集团股份有限公司 含抗tslp抗体的药物组合物
CR20230533A (es) * 2021-04-19 2024-04-05 Medimmune Ltd Un fab anti-tslp con estabilidad mejorada
EP4326766A1 (en) 2021-04-23 2024-02-28 Amgen Inc. Anti-tslp antibody compositions and uses thereof
US20240182558A1 (en) 2021-04-23 2024-06-06 Amgen Inc. Modified anti-tslp antibodies
CN113683694B (zh) * 2021-09-03 2022-05-13 江苏荃信生物医药股份有限公司 一种抗人tslp单克隆抗体及其应用
CN116217724B (zh) * 2021-12-02 2023-10-27 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用
CN117327176A (zh) * 2022-06-24 2024-01-02 南京融捷康生物科技有限公司 一种抗tslp的单域抗体及其用途
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
AR130862A1 (es) 2022-10-26 2025-01-29 Amgen Inc Composiciones de anticuerpos anti-tslp y usos de las mismas
TW202523697A (zh) * 2023-08-25 2025-06-16 美商普羅特歐拉吉克適美國公司 抗tslp抗體構築體及其用途
WO2025049345A1 (en) 2023-08-25 2025-03-06 Proteologix Us Inc. Anti-il-13 multispecific antibody constructs and uses thereof
CN117551195B (zh) * 2024-01-12 2024-04-09 杭州畅溪制药有限公司 靶向tslp的vhh纳米抗体及其应用
WO2025179220A1 (en) * 2024-02-22 2025-08-28 Flagship Pioneering Innovations Vi, Llc Dosing of antigen binding molecules targeting thymic stromal lymphopoietin (tslp)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
AU675661B2 (en) 1992-07-24 1997-02-13 Abgenix, Inc. Generation of xenogeneic antibodies
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
US7982016B2 (en) * 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
TW201018482A (en) 2008-08-08 2010-05-16 Glaxo Wellcome Mfg Pte Ltd Novel treatment
JP6077856B2 (ja) 2009-11-04 2017-02-08 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 操作型抗tslp抗体本出願は、米国特許仮出願第61/297,008号(2010年1月21日出願)、および米国特許仮出願第61/258,051号(2009年11月4日出願)の利益を主張し、該仮出願は各々、引用によりその全体が本明細書に組み込まれる。
AR082163A1 (es) 2010-07-15 2012-11-14 Hoffmann La Roche Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos
US9100245B1 (en) 2012-02-08 2015-08-04 Amazon Technologies, Inc. Identifying protected media files
US9306926B2 (en) 2013-03-15 2016-04-05 Brian A. Truong User authentication using unique hidden identifiers
SG11201603127WA (en) * 2013-10-23 2016-05-30 Genentech Inc Methods of diagnosing and treating eosinophilic disorders
SG11201700901SA (en) * 2014-08-08 2017-03-30 Alector Llc Anti-trem2 antibodies and methods of use thereof
CN107428828A (zh) * 2015-03-11 2017-12-01 葛兰素史密斯克莱知识产权发展有限公司 Tslp结合蛋白
EA038332B1 (ru) 2015-09-09 2021-08-10 Новартис Аг Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
JOP20190243A1 (ar) * 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp

Similar Documents

Publication Publication Date Title
JP2024150751A5 (enExample)
JP7766392B2 (ja) 治療用抗cd40リガンド抗体
JP2022105178A (ja) 黄色ブドウ球菌(staphylococcus aureus)感染症を治療および予防するための組成物および方法
JP2018183173A5 (enExample)
JP6513657B2 (ja) Il−17a結合剤およびその用途
JP2020509756A5 (enExample)
JP2008502366A5 (enExample)
JP2013056885A5 (enExample)
JP2018519364A5 (enExample)
JP2019527194A5 (enExample)
ME02371B (me) Sastojci i postupci za dijagnstikovanje i tretman raka
US20240209082A1 (en) Anti-cd96 antibodies and methods of use thereof
RU2019140602A (ru) АНТИ-GARP-TGF-β-АНТИТЕЛА
JP2010536378A5 (enExample)
JPWO2019147831A5 (enExample)
JPWO2018191479A5 (enExample)
JP2018522540A5 (enExample)
JP2018529635A5 (enExample)
JP2020527152A5 (enExample)
JP2013508292A5 (enExample)
JP2020502233A5 (enExample)
RU2019140933A (ru) Средства, пути применения и способы лечения
JP2018529661A5 (enExample)
JP2020504135A5 (enExample)
JPWO2020180819A5 (enExample)